Compounds > erlotinib hydrochloride
Page last updated: 2024-09-05

erlotinib hydrochloride and Body Weight

erlotinib hydrochloride has been researched along with Body Weight in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (14.29)18.2507
2000's2 (28.57)29.6817
2010's4 (57.14)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Beijnen, JH; Huitema, AD; Knapen, LM; Lankheet, NA; Schellens, JH; Steeghs, N1
Iseri, K; Iyoda, M; Kuno, Y; Matsumoto, K; Saito, T; Shibata, T; Shindo-Hirai, Y; Suzuki, T; Wada, Y; Yamamoto, Y1
Alexandre, J; Arrondeau, J; Bigot, F; Blanchet, B; Boudou-Rouquette, P; Cessot, A; Chapron, J; Goldwasser, F; Huillard, O; Thomas-Schoemann, A; Tlemsani, C; Vidal, M1
Hare, KJ; Hartmann, B; Holst, JJ; Poulsen, SS; Rasmussen, AR; Thim, L; Viby, NE1
Boockvar, JA; Edgar, MA; Karampelas, I; Luther, N; Souliopoulos, EP; Souweidane, MM1
Conklin, E; Dwyer-Nield, LD; Eckhardt, SG; Fritz, JM; Gustafson, DL; Iwata, KK; Kane, S; Malkinson, AM; Redente, EF; Shroyer, RJ; Tucker, C; Zerbe, LK1
Arnold, LD; Baker, DA; Barbacci, EG; Davis, JA; Doty, JL; Iwata, KK; Morin, MJ; Moyer, JD; Pollack, VA; Pustilnik, LR; Savage, DM; Sloan, DE; Smolarek, TA; Tsaparikos, KE; Vaidya, MP1

Trials

1 trial(s) available for erlotinib hydrochloride and Body Weight

ArticleYear
Erlotinib pharmacokinetics: a critical parameter influencing acute toxicity in elderly patients over 75 years-old.
    Investigational new drugs, 2017, Volume: 35, Issue:2

    Topics: Aged; Aged, 80 and over; Aging; Antineoplastic Agents; Body Height; Body Mass Index; Body Weight; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors

2017

Other Studies

6 other study(ies) available for erlotinib hydrochloride and Body Weight

ArticleYear
Plasma concentrations of tyrosine kinase inhibitors imatinib, erlotinib, and sunitinib in routine clinical outpatient cancer care.
    Therapeutic drug monitoring, 2014, Volume: 36, Issue:3

    Topics: Aged; Antineoplastic Agents; Benzamides; Body Weight; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Drug Monitoring; Erlotinib Hydrochloride; Female; Gastric Acid; Half-Life; Histamine H2 Antagonists; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Neoplasms; Outpatients; Piperazines; Protein Kinase Inhibitors; Proton Pump Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Sunitinib; Tandem Mass Spectrometry

2014
Epidermal growth factor receptor inhibition with erlotinib partially prevents cisplatin-induced nephrotoxicity in rats.
    PloS one, 2014, Volume: 9, Issue:11

    Topics: Animals; Antineoplastic Agents; Apoptosis; Body Weight; Cell Line; Chemical and Drug Induced Liver Injury; Cisplatin; ErbB Receptors; Erlotinib Hydrochloride; Humans; Kidney Tubules, Proximal; Liver; Macrophages; Male; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Rats; Rats, Sprague-Dawley; RNA, Messenger

2014
The intestinotrophic peptide, GLP-2, counteracts the gastrointestinal atrophy in mice induced by the epidermal growth factor receptor inhibitor, erlotinib, and cisplatin.
    Digestive diseases and sciences, 2010, Volume: 55, Issue:10

    Topics: Animals; Antineoplastic Agents; Atrophy; Body Weight; Cisplatin; Dose-Response Relationship, Drug; Drug Interactions; Erlotinib Hydrochloride; Female; Gastroenteritis; Gastrointestinal Tract; Glucagon-Like Peptide 2; Mice; Mice, Inbred Strains; Protein Kinase Inhibitors; Quinazolines

2010
Interstitial infusion of erlotinib in the rodent brain.
    Journal of experimental therapeutics & oncology, 2009, Volume: 8, Issue:2

    Topics: Animals; Body Weight; Brain; Brain Neoplasms; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Glioma; Microinjections; Neostriatum; Quinazolines; Rats; Rats, Nude

2009
Inhibition by erlotinib of primary lung adenocarcinoma at an early stage in male mice.
    Cancer chemotherapy and pharmacology, 2008, Volume: 62, Issue:4

    Topics: Adenoma; Animals; Antineoplastic Agents; Body Weight; Disease Models, Animal; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Injections, Intraperitoneal; Lung Neoplasms; Male; Mice; Mice, Inbred Strains; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Quinazolines; Sex Factors

2008
Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice.
    The Journal of pharmacology and experimental therapeutics, 1999, Volume: 291, Issue:2

    Topics: Animals; Antineoplastic Agents; Body Weight; Cell Division; Cisplatin; Dose-Response Relationship, Drug; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Mice; Mice, Nude; Phosphorylation; Phosphotyrosine; Polypharmacy; Quinazolines; Time Factors; Transplantation, Heterologous; Tumor Cells, Cultured; Tyrosine

1999